WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1990002563) ANTIGENS OF SCHISTOSOMA MANSONI
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1990/002563    International Application No.:    PCT/GB1989/001049
Publication Date: 22.03.1990 International Filing Date: 06.09.1989
Chapter 2 Demand Filed:    02.04.1990    
IPC:
A61K 39/00 (2006.01)
Applicants: MEDICAL RESEARCH COUNCIL [GB/GB]; 20 Park Crescent, London W1N 4AL (GB) (For All Designated States Except US).
SIMPSON, Andrew, John, George [GB/GB]; (GB) (For US Only).
SMITHERS, Sidney, Ronald [GB/GB]; (GB) (For US Only)
Inventors: SIMPSON, Andrew, John, George; (GB).
SMITHERS, Sidney, Ronald; (GB)
Agent: KEITH W NASH & CO; Pearl Assurance House, 90-92 Regent Street, Cambridge CB2 1DP (GB)
Priority Data:
8821001.8 07.09.1988 GB
8829429.3 15.12.1988 GB
8906513.0 21.03.1989 GB
Title (EN) ANTIGENS OF SCHISTOSOMA MANSONI
(FR) ANTIGENES DE SCHISTOSOMA MANSONI
Abstract: front page image
(EN)A vaccine against $i(S. mansoni) comprises at least one antigen present in the surface membrane of the adult $i(S. mansoni) worm (mb-S) and capable of provoking an immune response. The vaccine may comprise mb-S itself, but preferably comprises only useful antigen(s) of mb-S active in provoking an immune response. One or more of the M¿r? 25K, 22K, 15K and 13K antigens of mb-S are most favoured as the basis of the vaccine.
(FR)Un vaccin contre le $i(S. mansoni) comprend au moins un antigène présent dans la membrane de surface du ver $i(S. mansoni) (mb-S) adulte et capable de provoquer une réponse immunitaire. Ledit vaccin peut comprendre le mb-S lui-même, mais ne comprend de préférence que des antigènes utiles de mb-S actifs pour provoquer une réponse immunitaire. Un ou plusieurs des antigènes M¿2?, 25K, 22K, 15K et 13K de mb-S sont préférés pour constituer la base du vaccin.
Designated States: GB, JP, US.
European Patent Office (AT, BE, CH, DE, FR, GB, IT, LU, NL, SE).
Publication Language: English (EN)
Filing Language: English (EN)